Robert Horlick - San Diego CA, US David King - Encinitas CA, US Peter Bowers - San Diego CA, US Jennifer Dalton - Cardiff CA, US Betty Wu - San Diego CA, US Traci Roberts - San Diego CA, US Xue Zhang - San Diego CA, US Laurence Altobell, III - San Diego CA, US
The disclosure relates to an isolated IL-17-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1 and optionally an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23 are replaced with a different residue. The disclosure also provides vectors, compositions, and methods of using the IL-17-binding agent to treat an IL-17-mediated disease.